Spectral Diagnostics Net Long-Term Debt 2010-2024 | EDTXF
Spectral Diagnostics net long-term debt from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
| Spectral Diagnostics Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $7 |
| 2023 | $3 |
| 2022 | $5 |
| 2021 | $N/A |
| 2020 | $N/A |
| 2019 | $N/A |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| 2010 | $N/A |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.163B | $0.002B |
| Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada. | |||